Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Total Non-Current Liabilities data on record, last reported at $306.0 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 7.12% year-over-year to $306.0 million; the TTM value through Dec 2025 reached $306.0 million, down 7.12%, while the annual FY2025 figure was $306.0 million, 7.12% down from the prior year.
  • Total Non-Current Liabilities reached $306.0 million in Q4 2025 per FHTX's latest filing, up from $294.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $422.8 million in Q4 2021 and bottomed at $104.9 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $349.2 million, with a median of $370.8 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 290.36% in 2022, then dropped 10.29% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $422.8 million in 2021, then dropped by 4.26% to $404.7 million in 2022, then decreased by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then fell by 7.12% to $306.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $306.0 million in Q4 2025, $294.0 million in Q3 2025, and $302.1 million in Q2 2025.